Short answer
Anika Therapeutics, Inc. (ANIK) filed an 8-K current report with the SEC on November 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for quarter ended September 30, 2026.
Anika Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Full results and management commentary available in Exhibit 99.1
- Investor focus: quarterly revenue, profitability, cash flow and guidance disclosed in the accompanying release
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $30.6M, up 10%, with Commercial Channel growth 17% and OEM growth 5%
- Gross margin expanded to 62% from 56%, while adjusted EBITDA increased to $5.1M from $0.9M
- New 10-year Hyvisc partnership includes $8M expected payments, including $4M upfront in Q1 2027
- 2026 guidance improved: revenue growth range 6%-10%, adjusted EBITDA margin range 15%-17%
- Hyalofast PMA deemed not approvable, creating regulatory risk despite ongoing efforts toward a future U.S. approval
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Anika Therapeutics, Inc. 8-K filings
Get the next ANIK 8-K as it lands
Follow ANIK for push alerts, or ask the research agent what this filing means.